Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

91/433 Matches for
“EASL, European Association for the Study of the Liver”

“EASL, European Association for the Study of the Liver” Clear all
  1. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 100

    the European Association for the Study of the Liver, European Association for

    FibroTest NashTest Metabolic

  2. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 100

    FibroTest SteatoTest Metabolic

  3. Late presentation of chronic viral hepatitis for medical care: a consensus definition.

    Mauss S et al. · BMC Med · 2017 Match 99

    the European Association for the Study of the Liver, experts from the

    FibroTest HBV HCV

  4. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Match 99

    FibroTest Metabolic

  5. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.

    Canivet CM et al. · Hepatology · 2023 Match 98

    …Aims The European Association for the Study of the Liver (EASL) has…

    FibroTest Metabolic

  6. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 98

    for the severity of ASH-score system by the Obuchowski measures for

    AshTest Alcohol

  7. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 97

    ActiTest FibroTest HBV

  8. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 97

    ActiTest FibroTest HCV

  9. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 96

    study outcome was the negative predictive value (NPV) of LCR1-LCR2 for

    LCR1 LCR2 HCV

  10. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 96

    The coprimary study outcome was the negative predictive value of LCR1-LCR2…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  11. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 95

    Liver biopsy has historically been the gold standard for identifying advanced hepatic…

    FibroTest Alcohol

  12. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 94

    The prevalence of liver fibrosis varied between 0·7% and 25·7…

    FibroTest Other

  13. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 94

    FibroTest Alcohol

  14. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Match 93

    …or liver biopsy/Fibroscan). Efficacy was assessed by the percentage of patients…

    FibroTest HCV

  15. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 93

    Liver biopsy was the main diagnostic tool for 46.2% of the

    FibroTest Alcohol HBV HCV +3

  16. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 92

    ActiTest FibroTest HCV

  17. FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.

    Munteanu M et al. · Liver Int · 2014 Match 92

    FibroTest HBV

  18. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 91

    The study endpoint was advanced fibrosis on liver biopsy. ### Results NIT areas…

    FibroTest Metabolic

  19. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 91

    FibroTest Alcohol HBV HCV +3

  20. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 90

    …index calculated for the concordance analysis. Results Median age of 63 patients…

    FibroTest HCV

  21. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 90

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  22. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 89

    The primary objective of the present study was to investigate whether the

    ActiTest FibroTest NashTest SteatoTest +1

  23. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 88

    study highlighted in the USA the association between awareness of liver disease…

    ActiTest FibroTest Alcohol HBV +3

  24. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 88

    for the prediction of liver-related death. ### Aim To validate the 10…

    FibroTest Alcohol HBV HCV +1

  25. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment.

    Pokorska-Śpiewak M et al. · Clin Exp Hepatol · 2017 Match 87

    ### Aim Of The Study Was to evaluate liver disease severity in children…

    ActiTest FibroTest HBV HCV

  26. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 87

    …at the endpoint (death or cardiovascular event) for each liver pathology. In…

    FibroTest NashTest SteatoTest Metabolic

  27. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 86

    …This Review discusses the advantages and limitations of noninvasive methods for the

    ActiTest FibroTest NashTest SteatoTest +1

  28. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 86

    the validation of three blood tests used in NAFLD patients, FibroTest for

    ActiTest FibroTest SteatoTest Metabolic

  29. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 85

    …We evaluated the effect of sleeve gastrectomy (SG) on NAFLD using validated…

    FibroTest NashTest SteatoTest Metabolic

  30. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 85

    …This study aimed to investigate whether the biomarkers of MASLD included in…

    ActiTest FibroTest NashTest SteatoTest +1

  31. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 84

    of NAFLD and to evaluate the relationship between various types of liver

    FibroTest NashTest SteatoTest Metabolic

  32. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 83

    study was to analyze the limitations of similar European (Fatty Liver Inhibition…

    ActiTest FibroTest NashTest NashTest-2 +3

  33. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 83

    Liver biopsy is currently considered as the gold standard for fibrosis assessment…

    FibroTest HBV HCV HIV

  34. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 82

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  35. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 82

    …Using liver biopsy (LB) as a reference, we assessed the accuracy of

    FibroTest NashTest SteatoTest HIV

  36. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.

    Köksal İ et al. · Turk J Gastroenterol · 2018 Match 81

    Liver biopsy is considered the gold standard for assessment of fibrosis but…

    FibroTest HCV

  37. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 81

    …be effective in the prediction of primary liver cancer in patients without…

    FibroTest LCR1 LCR2 Alcohol +3

  38. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Match 80

    …essential for prompting surveillance and treatment. The aim of this study was…

    FibroTest HCV

  39. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 80

    …and biomarkers for liver fibrosis assessment and follow-up of hepatitis B…

    FibroTest HBV

  40. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 79

    …methodologies for disease screening and staging, which create the possibility of more…

    ActiTest FibroTest HCV

  41. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 79

    …be effective in the prediction of primary liver cancer in patients without…

    LCR1 LCR2 Alcohol HBV +4

  42. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 78

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for

    NashTest-2 SteatoTest-2 Metabolic

  43. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 77

    of this study was to construct a new quantitative test for the

    FibroTest NashTest SteatoTest Metabolic

  44. Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.

    Yakoob R et al. · Ann Gastroenterol · 2015 Match 77

    ### Background The aim of this study was to compare noninvasive biomarkers, FibroTest…

    ActiTest FibroTest HCV

  45. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.

    Patel K et al. · Aliment Pharmacol Ther · 2016 Match 76

    …Among the 33% of patients with +/-1 Ishak stage change, FS changes…

  46. Toward non-invasive assessment strategies in autoimmune hepatitis.

    Jerez Diaz D et al. · World J Hepatol · 2025 Match 76

    …This study evaluates the diagnostic performance of FibroTest-Actitest, transient elastography, and…

    ActiTest FibroTest AIH

  47. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 75

    ### Background Noninvasive tests are crucial for the management and follow-up of

    ActiTest FibroTest AIH

  48. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 75

    …influencing the performance of liver fibrosis biomarkers. Even after correction for DANA…

    FibroTest HBV HCV HIV +1

  49. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Match 74

    ### Background & Aims The first aim was to extend the validation of FibroTest…

    ActiTest FibroTest HBV

  50. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 74

    In the current era of therapy with direct-acting antiviral (DAAs) drugs…

    FibroTest HCV

  51. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 73

    …We aimed to validate the diagnostic utility of TE for liver fibrosis…

    FibroTest Alcohol

  52. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 72

    …could be utilised for the evaluation of liver fibrosis rather than other…

    FibroTest HCV

  53. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.

    Schmid P et al. · PLoS One · 2015 Match 72

    the diagnostic performance of seven non-invasive tests (NITs) of liver fibrosis…

    FibroTest HCV HIV

  54. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 71

    …to worsen the course of NAFLD and the liver disease makes diabetes…

    FibroTest Metabolic

  55. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 71

    FibroTest HCV

  56. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 70

    The AUROC for the diagnosis of the intermediate adjacent stages F2 vs…

    FibroTest Alcohol HBV HCV +1

  57. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 70

    The detection and quantification of liver fibrosis is a key factor for

    FibroTest HBV

  58. Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

    White DL et al. · Dig Dis Sci · 2012 Match 69

    The ethnically-divergent results for methadone associated fibrosis risk and finding of

    ActiTest FibroTest HCV

  59. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 69

    for use in alcoholic liver disease (ALD). The aims of this study

    FibroTest Alcohol

  60. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 68

    …Therefore, we aimed to study the course of liver disease after an…

    FibroTest HCV HIV

  61. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014 Match 68

    …one of the first composite liver fibrosis markers. This study aims, prospectively…

    FibroTest Alcohol

  62. Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.

    Kucharska M et al. · Adv Clin Exp Med · 2015 Match 67

    …Ease of implementation of these studies, no need for hospitalization of the

    FibroTest HCV

  63. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication

    Imbert-Bismut F et al. · Lancet · 2001 Match 66

    …We aimed, in our prospective study, to assess the predictive value of

    FibroTest HCV

  64. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.

    Miailhes P et al. · J Viral Hepat · 2011 Match 66

    …We compared the performance of TE with liver biopsy (LB) in patients…

    FibroTest HBV HIV

  65. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

    Asselah T et al. · Liver Int · 2018 Match 65

    …group for immediate treatment. We evaluated the safety and efficacy of sofosbuvir…

    FibroTest HCV

  66. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 65

    the LFP started to increase for men at the age of 30…

    FibroTest Alcohol HBV HCV +1

  67. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.

    Mbaye PS et al. · PLoS One · 2011 Match 64

    the test promoters suggested a fibrosis in 18% of cases for FT…

    FibroTest HBV

  68. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 64

    for the diagnosis of fibrosis as compared with FibroTest (FT) and liver

    FibroTest Alcohol HBV HCV +3

  69. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

    Colletta C et al. · Hepatology · 2005 Match 63

    …to the FibroTest in the noninvasive identification of fibrosis, for which excess…

    FibroTest HCV

  70. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

    Castéra L et al. · J Hepatol · 2010 Match 63

    study was to compare the performance of these two algorithms for diagnosing…

    FibroTest HCV

  71. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 62

    liver disease (NAFLD). ### Methods Cross-sectional study of subjects from the general…

    SteatoTest Metabolic

  72. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.

    Halfon P et al. · Comp Hepatol · 2002 Match 61

    for the prediction of the stage of liver fibrosis and grade of

    ActiTest FibroTest Alcohol HCV

  73. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Review

    Surial B et al. · Liver Int · 2021 Match 61

    …Our primary outcome was the prevalence of cirrhosis in HBsAg-positive persons…

    FibroTest HBV

  74. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Match 60

    The overall accuracy of AT for the diagnosis of any activity grade…

    ActiTest HCV

  75. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 60

    …Histologic staging of liver fibrosis served as the reference standard. ### Results Liver

    FibroTest Alcohol HBV HCV +2

  76. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Match 59

    The aim was to estimate the impact of SVR on the dynamic…

    FibroTest HCV

  77. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 59

    The study's risk of bias was assessed using the Quality Assessment…

    FibroTest Metabolic

  78. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 58

    Liver Fibrosis test and FibroTest have comparable performance for the diagnosis of

    FibroTest Alcohol

  79. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010 Match 58

    ### Background & Aims The diagnostic accuracy of non-invasive liver fibrosis tests that…

    FibroTest HBV HCV HIV

  80. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 57

    The performance of biopsy was lower for the diagnosis of F2 vs…

    FibroTest Alcohol HBV HCV +3

  81. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 57

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  82. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    Poynard T et al. · Hepatology · 2003 Match 56

    The biochemical markers have significant predictive values both for the diagnosis of

    ActiTest FibroTest HCV

  83. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 55

    the assessment of non-alcoholic fatty liver disease (NAFLD). Since liver biopsy…

    FibroTest Metabolic

  84. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 55

    …standard for assessing the severity of the most frequent chronic liver diseases…

    ActiTest FibroTest SteatoTest Alcohol +5

  85. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

    Boyd A et al. · J Int AIDS Soc · 2017 Match 54

    The aim of this study was to evaluate the evolution of liver

    FibroTest HBV HIV

  86. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 54

    …accurate diagnosis of cirrhosis and reduces the need for liver biopsy. In…

    FibroTest Alcohol HBV HCV +1

  87. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 53

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  88. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 53

    Liver biopsy is the reference standard for assessment of liver fibrosis. However…

    FibroTest HBV

  89. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 52

    ActiTest FibroTest HBV

  90. Ministère des Affaires Sociales et de la Santé Key publication

    Match 52

    FibroTest HBV HCV

  91. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 51

    FibroTest HBV

Showing the full result list. The page is server-rendered and not paginated.